Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer

Santiago Ponce Aix, Denis Talbot, Ramaswamy Govindan, Manuel Cobo Dols, Pieter E. Postmus, Conrad Lewanski, Jaafar Bennouna, Juergen R. Fischer, Oscar Juan-Vidal, David J. Stewart, Andrea Ardizzoni, Rafia Bhore, Marianne Wolfsteiner, Martin Reck, Teng Jin Ong, Daniel Morgensztern

Research output: Contribution to journalArticle

Abstract

Aim: Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line nab-paclitaxel ± durvalumab. Patients & methods: Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core. Results: QoL was generally stable through eight treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in Lung Cancer Symptom Scale (overall constitutional score and three-item index [nab-paclitaxel + durvalumab]) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core (global health status/QoL and emotional functioning [both arms] and pain [nab-paclitaxel + durvalumab]) analyses. EuroQoL Five-Dimensions Five-Levels domains were stable/improved or completely resolved at least once in 19-56% and 9-51% of patients, respectively. Conclusion: While QoL trends were promising, additional data are required to support these regimens in this setting.

Original languageEnglish
Pages (from-to)749-762
Number of pages14
JournalFuture Oncology
Volume16
Issue number12
DOIs
StatePublished - Apr 2020

Keywords

  • EORTC QLQ-C30
  • EQ-5D-5L
  • durvalumab
  • lung cancer symptom scale
  • nab-paclitaxel
  • non-small cell lung cancer
  • quality of life

Fingerprint Dive into the research topics of 'Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Ponce Aix, S., Talbot, D., Govindan, R., Dols, M. C., Postmus, P. E., Lewanski, C., Bennouna, J., Fischer, J. R., Juan-Vidal, O., Stewart, D. J., Ardizzoni, A., Bhore, R., Wolfsteiner, M., Reck, M., Ong, T. J., & Morgensztern, D. (2020). Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer. Future Oncology, 16(12), 749-762. https://doi.org/10.2217/fon-2019-0796